Ozari Health has rolled out a nationwide telehealth platform offering two structured plans for compounded GLP-1 medications — a move that signals continued market maturation in the direct-to-consumer weight-management space as demand for semaglutide and tirzepatide remains historically elevated.
The platform launches with two distinct tiers. Ozari One delivers compounded semaglutide combined with B12 at $86 per month, or compounded tirzepatide with B12 at $125 per month. Ozari Select offers patients a choice of formulation, billing term, and dispensing pharmacy. Both plans are available in all 50 states, include the provider consultation and free shipping, and carry no recurring membership fee — a pricing structure designed to lower friction for patients who have previously faced unpredictable cost escalation as they titrate to higher maintenance doses.
The Formulation Angle
The inclusion of vitamin B12 alongside the GLP-1 active ingredient reflects a broader formulation trend in compounded weight-management products, where ancillary micronutrients are bundled to address known nutritional gaps in patients undergoing caloric restriction. B12 deficiency risk is a documented concern in populations using GLP-1 receptor agonists long-term, and its co-formulation positions Ozari's offering within the broader weight management and metabolic health conversation that has come to dominate functional nutrition and nutraceutical strategy across the supply chain.
Ozari's platform carries LegitScript certification, a third-party credentialing standard that verifies adherence to applicable pharmacy and telehealth regulations — an increasingly important differentiator as the FDA and state pharmacy boards intensify scrutiny of 503A compounding operations. The company publicly names five US-licensed 503A compounding pharmacies that fulfill its prescriptions, a transparency measure that distinguishes it from platforms that obscure their dispensing partners. 503A pharmacies compound medications on a patient-specific, prescription basis and operate under a distinct regulatory framework from the FDA-approved branded formulations manufactured by Novo Nordisk and Eli Lilly.
Market Context
The GLP-1 telehealth segment has expanded rapidly since compounded versions of semaglutide and tirzepatide became accessible during periods of FDA-declared shortage. Operators across the supplements and ingredients category — from contract manufacturers to ingredient suppliers — have tracked this space closely, as adjacent demand for appetite-regulating botanicals, protein-fortified formats, and muscle-preservation nutraceuticals has grown in lockstep with GLP-1 patient populations. Registered dietitians and functional medicine practitioners increasingly cite GLP-1 users as a distinct consumer cohort requiring tailored nutritional support, particularly around protein intake, electrolyte balance, and micronutrient repletion.
Flat-rate pricing that holds constant across dose escalation is a structural differentiator in a market where competing platforms often charge incrementally as patients move from starting doses to therapeutic maintenance levels. For operators and retailers building GLP-1-adjacent product portfolios, the growth of accessible, lower-cost telehealth entry points suggests the addressable patient base will continue to widen through 2026 and beyond.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
